Afatinib Dimaleate Intermedia CAS 314771-88-5 Puritas >99.0% (HPLC) Factory

Description:

Chemical Name: (S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-Amine

CAS: 314771-88-5

Puritas: >99.0% (HPLC)

Aspectus: Yellow ut lux Yellow pulveris

Afatinib Dimaleate (CAS: 850140-73-7)

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum (S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-Amine
Synonyma N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-[(3S)-oxolan-3-yl] oxyquinazolin-4-Amine;7-((S)-Tetrahydrofuran-3-yloxy) -4-(3-Chloro-4-Fluorophenyl)amino-6-Nitroquinazoline;Afatinib immunditia
CAS Number 314771-88-5
CATTUS Number RF-PI2027
Stock Status In Stock, Productio Ascendite ad Tons
Formulae hypotheticae C18H14ClFN4O4
M. Pondus 404.78
Density 1.534±0.060 g/cm3
Brand Ruifu Chemical

Specifications:

Item Specifications
Aspectus Yellow ad lux flavo pulveris
Puritas / Analysis Methodus >99.0% (HPLC)
Damnum in Siccatio <0.50%
Individual Impurity <0.50%
Totalis immunditias <1.00%
Metalla gravis ≤20ppm
Test Standard Enterprise Standard
Consuetudinem Afatinib Dimaleate (CAS: 850140-73-7)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

1

FAQ:

Applicatio:

(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-Amine (CAS: 314771-88-5) adhibetur in Praeparatio Afatinib Dimaleate (CAS: 850140-73-7).Afatinib est porttitor anti-cancri scopum medicamentum, nova generatio scopo oralis medicamento, primum pharmacum anti-cancri scopum mundi, quod irreversibiliter obligat ad familiam ErbB, et efficacior est et iaculis impedit signum quod incrementum cellulis cancri trigger. reducendo vel differendo cellularum cancri multiplicationem.Afatinib ad genus medicamentorum quae inhibitores tyrosini kinase vocantur.Munus duorum servo propinquorum arcte intercluso operatur, factor incrementi epidermalis receptoris (EGFR) et factor incrementi humani epidermalis receptoris 2 (ER2).Usus primae lineae curationis aegrorum cum cancro metastatico cellae pulmonis non parvae.Afatinib est porttitor anti-cancri scopum medicamentum, nova generatio scopo oralis medicamento, primum pharmacum anti-cancri scopum mundi, quod irreversibiliter obligat ad familiam ErbB, et efficacior est et iaculis impedit signum quod incrementum cellulis cancri trigger. reducendo vel differendo cellularum cancri multiplicationem.

Epistulam tuam hic scribe et mitte nobis